
The Edge Gap: Why Experimentation Is Important For Brands In 2025
In 2025, the biggest risk in marketing isn't making a bold move—it's playing by the book.
AI-driven tools have made marketing faster, smarter and more scalable. But they've also created a paradox: When everyone is using the same software, platforms, targeting models and campaign techniques, competitive advantage collapses. Best practice has quietly become common practice, and that's where the danger lies.
I'm in conversation with at least 10 new brands per week. Nine out of 10 of them say the same thing: What's "tried and tested" isn't working anymore. Some blame the algorithm. Others realize they've become too cautious.
This is the "edge gap"—the space between brands optimizing for efficiency and those exploring for effectiveness. The only way to close it without wasting budget? Treat experimentation not as a tactic, but a mindset—a strategic advantage in an overly risk-averse landscape.
Marketing in 2025 is marked by an uncomfortable truth: Everyone is using the same tools to chase the same outcomes.
Meta's Advantage+ campaigns hit a $20 billion annual run rate in Q4 2024—a 70% year-over-year increase. Meanwhile, 95% of retail advertisers using shopping ads have adopted Google's Performance Max, according to Tinuiti's Digital Ads Benchmark Report Q4 2024.
These aren't just trends; they're signs of a marketing ecosystem that's been optimized into sameness.
This is the edge gap in practice: the growing divide between brands that stick with automated, AI-driven campaign systems and then focus on efficiency, versus those actively exploring new paths to stand out.
The edge gap is the widening space between marketing strategies that sharpen a brand's competitive edge and those dulled by algorithmic automation, uniform targeting and the rinse-and-repeat logic of platform and industry best practice.
It's not a theory; from the clients I speak to, there are signals across the industry that marketers chasing a competitive edge are starting to walk away from "black box" campaign types in search of something more original.
Algorithms don't just optimize—they homogenize. And we're all using the same targeting technology. So when every brand plays by the same rules, creative solutions become the only way to get a competitive advantage within your advertising.
Many brands think they're innovating, but they're only tweaking. Adding more data, cutting "wasted spend" or rotating similar creatives may boost ROI, but these are optimizations, not exploration, and rarely drive real revenue growth.
Exploration means going off script and testing bold ideas outside the industry playbook. It's trying unfamiliar channels, formats or creative styles, and even breaking tools to use them differently.
The trap is that iteration feels safe. It offers progress without disruption and wins boardroom approval with fast, measurable results. But over-optimizing what already exists limits exploration and weakens long-term performance. Real progress needs a system, one built on experimentation.
Experimentation is the antidote to risk-averse marketing.
It gives brands a way to explore bold ideas without betting the entire budget. It's not guesswork, and it's not chaos—it's a system for learning. It's a way to try before you buy, measure before you scale and push boundaries with purpose.
High risk can equal high reward. But experimentation works as the arbitrator, minimizing those risks by testing parts of the strategy before deciding where to invest fully. It gives teams the confidence to try something genuinely different, without getting shut down at the first sign of uncertainty.
The upside is well documented. Bain has highlighted countless examples where marketing experimentation has driven measurable ROI growth. And yet, McKinsey reports that only 25% of C-level marketers say they've embedded a test-and-learn culture into their teams.
The gap isn't one of knowledge—it's one of commitment.
Too often, data and analytics teams are focused on proving value, not growing it. They're looking backward at what worked, not forward at what could.
Experimentation flips that model. It uses data as a launchpad for future media effectiveness, not just past efficiency.
Saying you value experimentation is easy, but embedding it into how your team thinks and works is far harder. The best brands share three traits:
They reward original thinking and protect teams who take risks. Failure is essential for discovery. At Impression, some of our best-performing ads started as long shots. True creative progress requires leadership to back bold testing, financially and culturally.
Not every idea needs testing, and not all tests deliver instant results. Smart teams prioritize high-impact hypotheses, bets that, if right, unlock real growth. Too often, testing is used only to justify spend, leading to cautious, shallow efforts that are cut too soon. Real learning requires time and commitment.
Without structure, testing loses credibility. Vague or biased experiments create confusion, not clarity. That's why rigorous data science is nonnegotiable. It means setting clear hypotheses, managing variables, using control groups and ensuring significance before declaring wins.
Strong teams treat experimentation as a continuous system for learning, not one-off projects.
In a marketing world increasingly shaped by black-box automation and AI, we've been guilty of adjusting our businesses' goals to fit the platform's best practices.
But when everyone is optimizing using the same tools, best practice becomes common practice.
Standing still is falling behind.
Experimentation isn't just a tactical add-on. It's a cultural capability, a mindset that allows your brand to move fast without falling into the sameness trap. It's how you test the unconventional and find your next breakthrough before your competitors do.
Because as we rocket through this decade, the edge gap will only widen. It will separate the brands that play it safe from the brands that grow.
Perhaps you're lucky right now … if your competitors are still following standard practice, you're probably doing fine. But that won't last. Eventually, someone in your category will decide to explore.
One type of brand will focus on iteration. The other will explore. And only one will survive.
Forbes Communications Council is an invitation-only community for executives in successful public relations, media strategy, creative and advertising agencies. Do I qualify?

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Former Nokia CEO joining Finnish quantum company's board
STOCKHOLM (Reuters) -Former Nokia CEO Pekka Lundmark will join Finnish quantum computing company QMill as an investor and a board member, the company said on Wednesday. Lundmark stepped down from the top job at Nokia earlier this year after being appointed as CEO in 2020, and is credited with turning around the telecom gear maker. Antti Vasara, former head of VTT Technical Research Centre of Finland, and a former Nokia executive, will also join QMill as chair of the board. Espoo, Finland-based QMill, is a quantum-algorithm company, which started operations last year, and has raised seed funding from Antler, and Kvanted. Quantum computing is emerging as a promising sector where many startups are working alongside tech companies such as Microsoft and Nvidia to build functional computers to solve problems that would take classical computers thousands of years. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
19 minutes ago
- Yahoo
Airbus workers to stage strikes amid pay dispute
Workers at aircraft manufacturer Airbus are to stage a series of strikes in a dispute over pay. Unite said around 3,000 of its members will walk out for 10 days in September after they voted overwhelmingly in favour of industrial action. Unite general secretary Sharon Graham said: 'Airbus is generating billions in profit; workers deserve a fair deal. Our members are simply seeking fairness not favours. 'Airbus workers have the total support of their union in this dispute.' Unite warned the strikes will hit production of wings for Airbus's commercial and military aircraft programmes.
Yahoo
19 minutes ago
- Yahoo
Coloplast AS (CLPBF) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amidst Challenges
This article first appeared on GuruFocus. Organic Revenue Growth: 7% for the third quarter. EBIT Margin Before Special Items: 28% in the third quarter. Adjusted Return on Invested Capital: 15%, on par with last year. Ostomy Care Organic Growth: 6% for the first nine months. Continence Care Organic Growth: 8% for the first nine months. Voice and Respiratory Care Organic Growth: 9% for the first nine months. Advanced Wound Care Organic Growth: 9% for the first nine months. Kerecis Growth: 26% for the first nine months. Interventional Urology Organic Growth: 1% for the first nine months. Gross Margin: 68% for the first nine months. Operating Profit Before Special Items: DKK 5.7 billion for the first nine months. Net Profit Before Special Items: DKK 3.8 billion for the first nine months. Operating Cash Flow: DKK 4.4 billion for the first nine months. Free Cash Flow: DKK 3.5 billion for the first nine months. CapEx: 5% of sales for the first nine months. Warning! GuruFocus has detected 4 Warning Signs with CLPBF. Release Date: August 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Coloplast AS (CLPBF) reported a 7% organic growth for the third quarter, driven by broad-based growth across its Chronic Care businesses. The company has reorganized its structure into two business units, Chronic Care and Acute Care, to better address market dynamics and customer needs. Coloplast AS (CLPBF) is focusing on innovation, with plans to bring new products to market faster and enhance R&D capabilities. The company has maintained a stable EBIT margin of 27% to 28% before special items, demonstrating effective cost management. Kerecis, a part of the Advanced Wound Care segment, showed strong growth of 26% in the first nine months, indicating robust demand for its products. Negative Points The Advanced Wound Care business fell short of expectations due to product returns in China and lower-than-expected growth for Kerecis. The US Centers for Medicare and Medicaid Services proposed rules that could impact Coloplast AS (CLPBF)'s Chronic Care business, introducing uncertainty about future financial impacts. The company faced a negative impact from foreign exchange rates, which reduced reported revenue by approximately 1%. Coloplast AS (CLPBF) experienced a product recall in China, leading to a significant negative financial impact in the third quarter. The Bladder Health and Surgery segment continued to detract from growth, with uncertainty around the timeline for full recovery. Q & A Highlights Q: Lars, we've seen product recalls and execution issues. What steps are you taking to prevent future recalls? A: Lars Rasmussen, Interim CEO: The recall of urological products was due to a sterilization barrier breach, a common issue in the industry. The situation in China with Biatain foam products is different; it's a technical specification issue unique to China, not a quality problem. We're discussing this with the market and working on substitute products, but it's a slow process. Q: Can you elaborate on the INTIBIA filing and your confidence in regulatory acceptance? A: Anders Lonning-Skovgaard, CFO: We are on track with the INTIBIA launch and expect to get it through the FDA process in the US. We anticipate launching in the first part of the next strategic period. Q: Regarding Kerecis, how was growth in non-physician office settings, and what are the incentives for physicians to use higher-priced products? A: Anders Lonning-Skovgaard, CFO: In Q3, high-priced products reentered the market due to an LCD delay, impacting sales. We expect a bounce back in Q4. The new skin substitute price is being discussed and expected to be implemented in January 2026. Q: On the competitive bidding proposal, can you provide more details on the potential impact on US Chronic Care sales? A: Lars Rasmussen, Interim CEO: It's difficult to estimate the impact, but competitive bidding on specialized products like Ostomy Care seems illogical due to the complexity and variety of SKUs. We estimate around 50% of our US sales are Medicare-related. Q: Can you explain the rationale behind establishing R&D franchises within Chronic Care? A: Lars Rasmussen, Interim CEO: Innovation is crucial, and we aim to bring products to market faster and derive more value from them. This change elevates R&D to the executive level to ensure close collaboration with manufacturing, enhancing both innovation and profitability. For the complete transcript of the earnings call, please refer to the full earnings call transcript.